Tirzepatide and HFpEF: What the SUMMIT Trial Means

Heart failure with preserved ejection fraction — HFpEF — is one of the most frustrating diagnoses in cardiology. Unlike heart failure with reduced ejection fraction (HFrEF), which has a well-established drug arsenal, HFpEF historically responded poorly to most traditional heart failure treatments. The heart contracts normally; the problem is that it can't relax and fill properly, typically in the context of obesity, hypertension, and metabolic disease.

The SUMMIT trial changed the treatment conversation. It demonstrated that tirzepatide — a GLP-1/GIP dual agonist developed for diabetes and obesity — produced clinically meaningful improvements in HFpEF symptoms, functional capacity, and patient-reported quality of life. This is what the trial actually showed, who it enrolled, and what the tirzepatide heart failure findings mean in practice.

What HFpEF Is (and Why It's Hard to Treat)

Heart failure with preserved ejection fraction means the left ventricle pumps blood out normally (ejection fraction ≥50%), but the heart muscle is stiff and doesn't relax well between beats. This impairs filling — less blood enters the ventricle per cycle, so less blood is pumped out, even if the fraction pumped looks normal.

The result: patients experience the classic symptoms of heart failure — exertional dyspnea (shortness of breath with activity), reduced exercise tolerance, fluid retention — despite a technically normal ejection fraction on echocardiogram.

HFpEF is heavily associated with:

• Obesity (BMI ≥30 is a common threshold in trials)
• Hypertension
• Type 2 diabetes
• Atrial fibrillation
• Chronic kidney disease
• Older age

The mechanistic connections to obesity are particularly relevant for the SUMMIT findings. Excess adipose tissue, particularly visceral and epicardial (around the heart) fat, contributes directly to cardiac stiffness, inflammation, and pericardial constraint. Weight loss that meaningfully reduces visceral and epicardial fat should, mechanistically, improve HFpEF — and SUMMIT tested whether tirzepatide delivered on that hypothesis.

SUMMIT Trial Design

Full name: SUMMIT — A Study of Tirzepatide in Participants With Heart Failure with Preserved Ejection Fraction and Obesity

Population: Adults with HFpEF (left ventricular ejection fraction ≥50%), BMI ≥30, and NYHA class II or III symptoms. 731 participants enrolled.

Design: Randomized, double-blind, placebo-controlled. Tirzepatide starting at 2.5 mg weekly, titrated up to 15 mg weekly, vs placebo, over 52 weeks.

Primary endpoints (dual primary):

1. Change in KCCQ-CSS (Kansas City Cardiomyopathy Questionnaire Clinical Summary Score) — a validated patient-reported outcomes measure that captures symptom burden and physical limitations from 0 to 100
2. Change in 6-minute walk distance (6MWD) — a functional exercise capacity measure

Secondary endpoints included:

• NYHA class change
• Worsening heart failure events (hospitalization or urgent visit for HF)
• Body weight
• Safety

Key Results

Both primary endpoints were met.

KCCQ-CSS: Tirzepatide improved clinical summary score by approximately 8.3 points more than placebo over 52 weeks. In HF outcomes research, a 5-point change in KCCQ is generally considered the minimum clinically important difference — the SUMMIT difference exceeded that threshold and was highly statistically significant.

6-minute walk distance: Tirzepatide-treated participants walked meaningfully farther than placebo at 52 weeks, demonstrating improvement in functional capacity that corresponds to the KCCQ symptomatic gains.

NYHA class improvement: 49% of tirzepatide participants improved by at least one NYHA class (e.g., from class III to class II, or II to I), versus 26% of placebo participants. This is a large and clinically meaningful difference.

Weight loss: Participants on tirzepatide lost approximately 13.1% of body weight over 52 weeks. This is somewhat lower than the SURMOUNT-1 result (15.0% at 5 mg at 72 weeks), which is expected — SUMMIT participants were older and more medically complex.

Worsening HF events: The trial showed a meaningful reduction in composite worsening HF events (hospitalization or urgent HF visit) with tirzepatide — an important finding because it suggests the benefit goes beyond symptom improvement to hard cardiovascular endpoints.

Safety: Serious adverse events were less common in the tirzepatide group than placebo, which partly reflects the cardiovascular protective effects of weight reduction and metabolic improvement. GI side effects (nausea, diarrhea, constipation) were consistent with the known tirzepatide profile.

Understanding the KCCQ Score

The Kansas City Cardiomyopathy Questionnaire (KCCQ) is worth explaining because it's become a standard endpoint in heart failure trials and its scores are what clinicians and regulators use to evaluate clinical meaningfulness.

The Clinical Summary Score (KCCQ-CSS) combines two subscales:

• Symptoms: frequency, severity, and the extent to which symptoms limit the patient's life
• Physical limitations: ability to perform specific activities (showering, walking, climbing stairs)

Scores range from 0 (worst) to 100 (best). In a population with class II–III HFpEF, baseline scores typically fall in the 50–65 range. An improvement of 5 points is considered the minimum clinically important difference — patients notice and report meaningful changes in daily life at that threshold.

SUMMIT's ~8-point advantage for tirzepatide over placebo represents a change that most patients can feel. For context: prior HFpEF trials with drugs like candesartan, spironolactone, and digoxin failed to show KCCQ improvements — or weren't studied with KCCQ as a primary endpoint — in this population.

NYHA Classification: What Moving a Class Means

The New York Heart Association (NYHA) functional classification grades heart failure severity:

SUMMIT enrolled Class II and III patients. Moving from Class III to Class II means a patient who previously got short of breath getting dressed or walking to the kitchen can now walk around more freely. Moving from Class II to Class I means returning to essentially normal physical function for daily life. Nearly half of tirzepatide participants improved a class — that's an outcome with immediate quality-of-life implications.

Who Qualifies: The Eligibility Picture

SUMMIT's enrollment criteria give the clearest indication of which patients are candidates for tirzepatide under this indication:

• HFpEF confirmed on echocardiogram (ejection fraction ≥50%)
• BMI ≥30 — obesity is a requirement for this indication; the benefit likely derives substantially from weight loss and related fat reduction
• NYHA class II or III — the trial didn't enroll class I (essentially asymptomatic) or class IV (end-stage) patients
• Stable on guideline-directed medical therapy for HF — participants were receiving appropriate background treatment

What this means: patients with HFpEF and normal or overweight BMI (below 30) were not studied in SUMMIT and are not candidates for this indication. The drug's label reflects the studied population.

People with HFrEF (reduced ejection fraction) are a different population — SUMMIT did not study them, and the HFpEF indication doesn't extend to them.

What the FDA Label Change Means

The SUMMIT trial led to an FDA labeling expansion for Zepbound to include reduction of cardiovascular death and worsening heart failure in adults with HFpEF and obesity. This matters for:

• Prescribing: Cardiologists and heart failure specialists can now prescribe Zepbound directly for HFpEF rather than coordinating with an obesity medicine or endocrinology prescriber
• Insurance: A cardiovascular indication — as opposed to a weight management indication — opens Part D coverage in Medicare, which historically excluded obesity drugs. Patients with Medicare Part D who have HFpEF and BMI ≥30 now have a coverage pathway that didn't exist before
• Clinical positioning: HFpEF is now on the cardiology management algorithm alongside renin-angiotensin-aldosterone system blockers, SGLT2 inhibitors (which also showed HFpEF benefit in the EMPEROR-Preserved trial), and MRA therapy

For cardiologists, tirzepatide now joins empagliflozin and dapagliflozin as drugs with demonstrated HFpEF benefit — a very different landscape than existed five years ago.

What It Doesn't Mean

The SUMMIT trial doesn't establish that tirzepatide is a first-line treatment for all HFpEF. The trial studied a specific population (obese HFpEF, class II–III) over 52 weeks. Several questions remain:

• What happens after 52 weeks? Long-term data on cardiovascular events (death, repeat hospitalization) at 3–5 years is not available from SUMMIT.
• Does the benefit require ongoing weight loss, or does it persist once metabolic and structural improvements are achieved?
• How does tirzepatide combine with SGLT2 inhibitors (which are now standard of care for HFpEF) — additive benefit is mechanistically plausible but not yet trial-established.

These aren't reasons to dismiss the SUMMIT findings — they're the normal limitations of a 52-week trial that established a new indication. Post-market studies and registry data will fill in the gaps over the next several years.

For patients with HFpEF, obesity, and class II–III symptoms who are currently on tirzepatide for weight management, SUMMIT provides strong evidence that staying on it has cardiovascular benefit beyond weight loss alone. For patients not yet on a GLP-1/GIP drug, it's now a formal conversation item with the cardiologist, not just the obesity medicine specialist.

Related reading

• Tirzepatide: the complete guide
• Tirzepatide sleep apnea: the SURMOUNT-OSA trial
• Tirzepatide visceral fat and MRI data
• Tirzepatide SURMOUNT trial results
• GLP-1 side effects guide